<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 12.2</label>
 <caption>
  <p>Clinical features, diagnosis, and treatment summary table</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Virus</th>
    <th>Population at risk</th>
    <th>Clinical and laboratory features</th>
    <th>Acute liver failure</th>
    <th>Unique complications</th>
    <th>Diagnostic tests</th>
    <th>Treatment</th>
    <th>Effective antiviral medication</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>EBV</td>
    <td>
     <p>IC</p>
     <p>Age &gt;30 (esp. &gt;60)</p>
     <p>XLP</p>
     <p>Solid organ transplant recipients (especially pediatric)</p>
    </td>
    <td>
     <p>Lymphocytosis</p>
     <p>Monocytosis</p>
     <p>Splenomegaly</p>
     <p>Gradually rising liver enzymes</p>
    </td>
    <td>
     <p>Rare</p>
     <p>More common in immunosuppressed patients (60 % in patients with XLP)</p>
    </td>
    <td>
     <p>Splenic rupture</p>
     <p>PTLD</p>
     <p>HLH</p>
     <p>AIH exac.</p>
    </td>
    <td>
     <p>Monospot</p>
     <p>EBV VCA IgM</p>
     <p>PCR (blood and tissue)</p>
     <p>Liver biopsy—rarely needed (portal and sinusoidal mononuclear cell infiltration with focal hepatic necrosis or fatty infiltration)</p>
    </td>
    <td>
     <p>ICP: only if severe complications</p>
     <p>Steroids</p>
     <p>Antivirals (if steroid refractory)</p>
     <p>IC: anti-EBV CTLs antivirals</p>
    </td>
    <td>
     <p>Ganciclovir</p>
     <p>Valganciclovir</p>
     <p>Valacyclovir</p>
     <p>Famiclovir</p>
     <p>Foscarent</p>
    </td>
   </tr>
   <tr>
    <td>CMV</td>
    <td>
     <p>IC</p>
     <p>Solid organ transplant recipients</p>
     <p>Neonates (congenital CMV)</p>
     <p>IBD</p>
    </td>
    <td>
     <p>Hepatosplenomegaly</p>
     <p>Aminotransferases lower than in “classic viral hepatitis”</p>
     <p>Leukopenia</p>
     <p>Thrombocytopenia</p>
    </td>
    <td>
     <p>Rare</p>
     <p>More common in IC</p>
    </td>
    <td>Graft rejection and loss encephalitis, pneumonitis, hepatitis, uveitis, retinitis, colitis</td>
    <td>
     <p>CMV IgM</p>
     <p>PCR (blood and tissue)</p>
     <p>Liver biopsy—important (giant multinucleated cell reaction with an inflammatory response, multifocal necrosis, biliary stasis. Large nuclear inclusions in hepatocytes or bile duct epithelium)</p>
     <p>Immuno-histochemistry</p>
    </td>
    <td>
     <p>ICP—only in severe end organ disease</p>
     <p>IC—antivirals ± IVIG</p>
     <p>Organ transplant recipients—prophylactic vs. preemptive treatment</p>
    </td>
    <td>
     <p>Ganciclovir</p>
     <p>Valganciclovir</p>
     <p>Foscarnet</p>
     <p>Cidofovir</p>
     <p>CMV hyperimmune globulin</p>
     <p>Leflunomide</p>
    </td>
   </tr>
   <tr>
    <td>HSV</td>
    <td>
     <p>IC</p>
     <p>Pregnancy (third trimester)</p>
     <p>Neonates</p>
    </td>
    <td>
     <p>Leukopenia, thrombocytopenia, relatively mild elevation in bilirubin</p>
     <p>Mucocutaneous lesions (50 %)</p>
    </td>
    <td>
     <p>Rare</p>
     <p>More common in pregnancy, IC, and neonates</p>
    </td>
    <td>
     <p>Esophagitis</p>
     <p>Pneumonitis</p>
    </td>
    <td>
     <p>HSV PCR (blood and tissue)</p>
     <p>Liver biopsy—essential (focal—extensive, hemorrhagic, or coagulative hepatocyte necrosis, limited inflammatory response). Typical intranuclear inclusions (Cowdry type A) at the margins of the foci of necrosis</p>
    </td>
    <td>Early high-dose acyclovir</td>
    <td>Acyclovir</td>
   </tr>
   <tr>
    <td>VZV</td>
    <td>
     <p>Adults</p>
     <p>IC</p>
     <p>Liver transplant recipients</p>
    </td>
    <td>Cutaneous rash</td>
    <td>
     <p>Rare</p>
     <p>More common in immunocompromised individuals</p>
    </td>
    <td>Graft loss</td>
    <td>
     <p>Viral isolation from skin lesions</p>
     <p>HSV PCR (blood and tissue)</p>
     <p>Liver biopsy (foci of coagulative necrosis and intranuclear inclusions with an inflammatory response)</p>
    </td>
    <td>Early therapy with acyclovir in severe disease or IC patients</td>
    <td>Acyclovir</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>IC</italic> immunocompromised, 
   <italic>ICP</italic> immunocompetent, 
   <italic>XLP</italic> X-linked lymphoproliferative disorder, 
   <italic>PTLD</italic> post-transplant lymphoproliferative disorder, 
   <italic>HLH</italic> hemophagocytic lymphohistiocytosis, 
   <italic>AIH</italic> autoimmune hepatitis, 
   <italic>CTLs</italic> cytotoxic T lymphocytes
  </p>
 </table-wrap-foot>
</table-wrap>
